For years, finasteride was available only in pill form. As a result, the only way to reduce DHT at the follicle level was to take a systemic drug that reduced DHT throughout the entire body. That changed as compounding technology made topical finasteride possible. The question of whether topical delivery can effectively support hair regrowth, while still lowering systemic exposure is significant, and the evidence now provides reasonably clear answers.
The Case for Topical Over Oral
The appeal of topical finasteride is clear. Oral finasteride at 1 mg daily reduces DHT levels through the body by about 70%. For most men, this systemic effect is well tolerated. But, for men who experience or are concerned about sexual side effects, reducing systemic DHT suppression while maintaining scalp-level effectiveness is ideal.
Topical delivery aims to concentrate the drug where it is needed — the scalp and the hair follicle — while reducing the drug's systemic bioavailability.
Topical finasteride is offers the advantage of localizing finasteride to the scalp, while minimizing systemic exposure, making it an ideal choice for those looking to minimize systemic side effects.
Key Comparative Studies
In one published study, men with androgenetic alopecia received either 0.25% topical finasteride solution daily or 1 mg oral finasteride daily. At study end, men had similar degrees of hair growth with significantly less systemic exposure to finasteride.
In general, while topical finasteride is drastically understudied compared to minoxidil, the full body of research suggests topical finasteride is comparable to oral finasteride when it comes to treating androgenetic alopecia. While systemic exposure varies depending on concentration and delivery vehicle, its a reliable alternative to minimize systemic exposure.
0.25% topical finasteride achieves scalp DHT suppression comparable to oral 1 mg finasteride while reducing systemic exposure. Clinical outcomes, though research is still limited, are comparable between the two.
Formulation and Concentration
Topical finasteride is available through compounding pharmacies at various concentrations.
While doses between 0.005% and 1% have been tested, most studies have used a concentration of 0.25%.
As a result, 0.25% represents the most evidence-based concentration, and the most reliable formulation to use for addressing androgenetic alopecia.
0.25% topical finasteride is the best-studied and most reliable concentration for hair loss.
Practical Considerations
Application: Topical finasteride is typically applied once daily to dry scalp, distributed to affected areas, and left to absorb. It is often combined with topical minoxidil in a single compounded formula for convenience.
Women and handling: Finasteride (whether oral or topical) should not be handled by women who are pregnant or may become pregnant. Topical exposure through skin contact is possible with the solution. Compounded formulas should be handled with care by female partners.
Compliance: Some patients prefer topical application because it fits into an existing scalp treatment routine. Others prefer the simplicity of a daily pill.
Cost: Compounded topical finasteride is not FDA-approved and is not covered by most insurance. Cost varies by compounding pharmacy but is generally comparable to or slightly higher than brand-name oral finasteride.
Who Is a Good Candidate for Topical Finasteride?
Topical finasteride is particularly appropriate for:
- ● Men who want finasteride's DHT-suppressing benefit with reduced systemic exposure
- Men who experienced side effects on oral finasteride and want to trial a lower-systemic-exposure version
- Men who prefer topical application and want to consolidate their scalp treatment into a single product
- Men who are already using topical minoxidil and want to add finasteride to the formula
Men who have been taking oral finasteride without side effects and are satisfied with their results have no clinical reason to switch.
Topical finasteride is a viable alternative to its oral counterpart. For men who prefer it or have concerns about systemic exposure, it is a comparable choice.
The Bottom Line
Topical finasteride at 0.25% achieves similar results to 1 mg oral finasteride while minimizing systemic exposure, although overall research is still limited. This makes topical finasteride an evidence-based alternative to oral finasteride for men who want the DHT-reducing effects of finasteride with reduced systemic exposure.